Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGARFiled 10 h ago

ResMed (RMD) reports a director or officer change

Open the sourceReported by SEC EDGAR, sec.gov, 19 November 2026, by SEC EDGAR

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

ResMed disclosed in a November 19, 2026 Form 8-K that director Ronald Taylor did not stand for re-election at the company’s November 18 annual meeting, cutting the board from 11 to 10 members. The same filing said the board’s compensation committee approved a new performance-based restricted stock unit agreement and fiscal 2027 grants to named executive officers, replacing recent awards tied to absolute and relative total shareholder return. The new design measures three-year performance against annual adjusted EPS and adjusted revenue goals, with one-third of target units allocated to each year and split evenly between the two metrics; threshold, target and maximum payouts are 50%, 100% and 200%, respectively. The shift matters because it ties more executive pay to recurring financial targets rather than stock performance alone, while the smaller board changes the governance backdrop. Investors will watch whether ResMed meets the new EPS and revenue thresholds and how the TSR modifier affects eventual share issuance.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR's report. It can get details wrong, so check the source.

Named in this story

ResMed (RMD), ResMed Inc., Ronald Taylor, Compensation and Leadership Development Committee

A linked name opens that asset's sentiment page.